A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients

Annals of Nuclear Medicine

Volumn 18, Issue 6, 2004, Pages 513-518

  Kurata, Seiji ^a   Ishibashi, Masatoshi ^a   Nishida, Hidemi ^a   Hiromatsu, Yuji ^a   Hayabuchi, Naofumi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone specific alkaline phosphatase; Bone to soft tissue ratio; Deoxypyridinoline; Renal osteodystrophy; Technetium 99m hydroxy methylene diphosphonate

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; DEOXYPYRIDINOLINE; OXIDRONATE TECHNETIUM TC 99M; PARATHYROID HORMONE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; BONE SCINTISCANNING; BONE SOFT TISSUE RATIO; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIALYSIS; FEMALE; FEMUR NECK; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LUMBAR SPINE; MAINTENANCE THERAPY; MALE; METABOLIC BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SENSITIVITY AND SPECIFICITY;

EID: 6944242455     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984569     Document Type: Article

References (23)

1. Malluche HH, Monier-Faugere MC. Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211.
2. Malluche HH, Langub MC, Monier-Faugere MC. The role of bone biopsy in clinical practice and research. Kidney Int 1999; 56 (Suppl 73): 20-25.
3. Olgaard K, Heerfordt J, Madsen S. Scintigraphic skeletal changes in uremic patients on regular hemodialysis. Nephron 1976; 17: 325-334.
4. Elder G. Review. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17: 2094-2105.
5. Balon BP, Bren A. Bone histomorphometry is still the golden standard for diagnosing renal osteodystrophy. Clin Nephrol 2000; 54: 463-469.
6. de Graaf P, Pauwels EKJ, Vos PH, Schicht IM, te Velde J, de Graeff J. Observations on computerized quantitative bone scintigraphy in renal osteodystrophy. Eur J Nucl Med 1984; 9: 419-425.
7. 99mTechnetium-tin-pyrophosphate bone scans in chronic renal failure. Clin Nephrol 1976; 6: 509-512.
8. Urena P, de Vemejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156.
9. Urena P, Hruby M, Ferreira A, Ang KS, de Vemejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512.
10. Urena P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 1995; 10: 932-939.
11. Schmidt-Gayk H, Drueke T, Ritz E. Non-invasive circulating indicators of bone metabolism in uraemic patients: can they replace bone biopsy? Nephrol Dial Transplant 1996; 11: 415-418.
12. Rosenthall L, Kaye M. Technetium-99m-pyrophosphate kinetics and imaging in metabolic bone disease. J Nucl Med 1975; 16: 33-39.
13. Sy WM, Mittal AK. Bone scan in chronic dialysis patients with evidence of secondary hyperparathyroidism and renal osteodystrophy. Br J Radiol 1975; 48: 878-884.
14. Wiegmann T, Rosenthall L, Kaye M. Technetium-99m-pyrophosphate bone scans in hyperparathyroidism. J Nucl Med 1977; 18: 231-235.
15. Fogelman I, Bessent RG, Gordon D. A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease. Eur J Nucl Med 1981;6: 93-97.
16. Francis MD, Ferguson DL, Tofe AJ, Bevan JA, Michaels SE. Comparative evaluation of three diphosphonates: in vitro adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). J Nucl Med 1980; 21: 1185-1189.
17. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709.
18. Johnson LC. Morphologic analysis in pathology: the kinetics of disease and general biology of bone. In: Bone biodynamics, Frost HM (ed), Boston; Little, Brown & Co., 1964: 543-654.
19. Schober HC, Han ZH, Foldes AJ, Shih MS, Rao DS, Balena R, et al. Mineralized bone loss at different sites in dialysis patients: Implications for prevention. J Am Soc Nephrol 1998; 9: 1225-1233.
20. de Jonge FAA, Pauwels EKJ, Hamdy NAT. Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure. Eur J Nucl Med 1991; 18: 839-855.
21. Rosenthall L. Radiophosphate imaging and bone densitometry in renal osteodystrophy. Curr Opin Nephrol Hypertens 1993; 2: 956-961.
22. Niwa T, Shiobara K, Hamada T, Miyazaki T, Tsukushi S, Uema K, et al. Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chimica Acta 1995; 235: 33-40.
23. Rosalki SB. Biochemical markers of bone turnover. Int J Clin Pract 1998; 52: 255-256.